Gain Therapeutics
GANX
50 hedge funds and large institutions have $17.4M invested in Gain Therapeutics in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.
242% more call options, than puts
Call options by funds: $246K | Put options by funds: $72K
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
19% more funds holding
Funds holding: 42 → 50 (+8)
10% more capital invested
Capital invested by funds: $15.8M → $17.4M (+$1.57M)
0.9% more ownership
Funds ownership: 19.4% → 20.3% (+0.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$589K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$283K |
| 3 |
Squarepoint
New York
|
+$251K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$239K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$651K |
| 2 |
Jane Street
New York
|
-$297K |
| 3 |
PCM
Potomac Capital Management
New York
|
-$115K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$47.5K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
-$42.4K |
GANX Hedge Fund Activity: Q2 2026 in Review
50 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2026, worth a combined $17.4M — up 9.9% from $15.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GANX positions and 4 closed out — a net gain of 8 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $589K. The largest seller was Susquehanna International Group, cutting an estimated $651K.
- 50 institutional investors held Gain Therapeutics (GANX) as of Q2 2026, up from 42 in Q1 2026.
- Funds reported $17.4M of Gain Therapeutics stock for Q2 2026, up 9.9% quarter-over-quarter.
- 12 funds opened new Gain Therapeutics positions in Q2 2026 and 4 closed out, a net change of +8 holders.
- The largest Gain Therapeutics buyer in Q2 2026 was GSA Capital Partners, an estimated $589K added.
- The largest Gain Therapeutics seller in Q2 2026 was Susquehanna International Group, an estimated $651K sold.
Based on aggregated 13F filings for Q2 2026.